MedTrace Logo

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

NCT04541381 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 860

Last updated 2026-05-07

No results posted yet for this study

Summary

Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants using pharmacogenomics/genotyping. Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications.

This is a randomized study, which means that participants in this study will be randomly assigned (as if "by flip of a coin") to one of two different groups: a "pharmacogenomics group" or "control group".

Conditions

Interventions

OTHER

Availability of clinical decision support based on pharmacogenomic results.

Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.

Sponsors & Collaborators

  • National Human Genome Research Institute (NHGRI)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Peter H. O'Donnell, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2027-10-01
Completion
2028-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04541381 on ClinicalTrials.gov